Rajbharan Yadav

8PUBLICATIONS
68CO-AUTHORS
Molecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical bacteriologyBiomedical fluid mechanicsMedical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 07, 2026
Combined antagonism of Oncostatin M (OSM) and Interleukin 6 (IL-6) provides both anti-fibrotic and anti-inflammatory benefit in pulmonary fibrosis.

Rojo A Ratsimandresy, Emma Doran, Hart S Dengler

|May 28, 2022
Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies.

Rajbharan Yadav, Siddharth Sukumaran, Tanja S Zabka

|Jan 12, 2022
Oncostatin M expression induced by bacterial triggers drives airway inflammatory and mucus secretion in severe asthma.

Sarah E Headland, Hart S Dengler, Daqi Xu

|Aug 05, 2021
TGFβ2 and TGFβ3 isoforms drive fibrotic disease pathogenesis.

Tianhe Sun, Zhiyu Huang, Wei-Ching Liang

|Oct 23, 2019
Meropenem-Tobramycin Combination Regimens Combat Carbapenem-Resistant Pseudomonas aeruginosa in the Hollow-Fiber Infection Model Simulating Augmented Renal Clearance in Critically Ill Patients.

Rajbharan Yadav, Phillip J Bergen, Kate E Rogers

|Aug 15, 2018
Meropenem Combined with Ciprofloxacin Combats Hypermutable Pseudomonas aeruginosa from Respiratory Infections of Cystic Fibrosis Patients.

Vanessa E Rees, Rajbharan Yadav, Kate E Rogers

Pageof 2

Frequent Collaborators

3 joint publications

Jürgen B Bulitta

3 joint publications

Alexander R Abbas

3 joint publications

Joseph R Arron

3 joint publications

Jason Vander Heiden